Insider · CIK 1798679
Masaru Matsuda
- EVP, Chief Legal Officer at Arcutis Biotherapeutics ARQT: 2 buys, 38 sales
- SVP, General Counsel at Halozyme Therapeutics HALO: 0 buys, 0 sales
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys2
Open-market sales38
Bought$19K
Sold$4.9M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Nov 4, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 40,000 sh at $34.32 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as the company's 8-K filed Nov 4, 2026. | $1.4M | 111,289 −26% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as the company's 8-K filed Nov 4, 2026. |
| Nov 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,219 sh at $31.86 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $39K | 111,289 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Sep 16, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 3,674 sh at $25.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 16, 2026. | $92K | 112,508 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 16, 2026. |
| Sep 8, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 9,989 sh at $25.03 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 8, 2026. | $250K | 116,182 −8% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 8, 2026. |
| Aug 3, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,230 sh at $26.12 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Aug 3, 2026. | $32K | 126,171 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Aug 3, 2026. |
| May 4, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 7,372 sh at $23.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed May 4, 2026. | $172K | 127,573 −5% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed May 4, 2026. |
| May 4, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 884 sh at $23.61 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed May 4, 2026. | $21K | 126,689 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed May 4, 2026. |
| Mar 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 6,553 sh at $25.16 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. | $165K | 137,125 −5% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. |
| Mar 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 193 sh at $25.91 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. | $5K | 136,932 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. |
| Mar 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,987 sh at $25.70 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. | $51K | 136,932 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Mar 2, 2026. |
| Feb 27, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 3,325 sh at $27.95 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 2 days after the company's S-3ASR filed Feb 25, 2026. | $93K | 143,678 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 2 days after the company's S-3ASR filed Feb 25, 2026. |
| Feb 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 7,983 sh at $25.50 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. | $204K | 142,658 −5% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. |
| Feb 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 8,562 sh at $24.97 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. | $214K | 134,096 −6% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. |
| Feb 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 19,379 sh at $25.24 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. | $489K | 114,717 −14% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. |
| Feb 2, 2026 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 4,714 sh at $25.63 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. | $121K | 110,003 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 2, 2026. |
| Dec 1, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,657 sh at $30.23 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Dec 1, 2025. | $50K | 150,641 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Dec 1, 2025. |
| Nov 19, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 989 sh at $27.95 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 19, 2025. | $28K | 153,037 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 19, 2025. |
| Nov 19, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,561 sh at $28.50 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 19, 2025. | $44K | 151,476 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 19, 2025. |
| Nov 3, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 7,165 sh at $24.71 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2025. | $177K | 154,069 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2025. |
| Nov 3, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 43 sh at $25.40 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2025. | $1K | 154,026 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2025. |
| Sep 4, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 36,130 sh at $16.16 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 4, 2025. | $584K | 161,234 −18% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Sep 4, 2025. |
| Aug 4, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 6,330 sh at $14.33 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 81 days after the company's SCHEDULE 13G/A filed May 15, 2025. | $91K | 197,364 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 81 days after the company's SCHEDULE 13G/A filed May 15, 2025. |
| May 28, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,800 sh at $13.78 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 13 days after the company's SCHEDULE 13G/A filed May 15, 2025. | $25K | 202,599 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 13 days after the company's SCHEDULE 13G/A filed May 15, 2025. |
| May 2, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 5,030 sh at $15.20 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 22 days after the company's 8-K filed Apr 10, 2025. | $76K | 204,399 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 22 days after the company's 8-K filed Apr 10, 2025. |
| Mar 3, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 3,263 sh at $13.03 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 6 days after the company's 8-K filed Feb 25, 2025. | $43K | 209,429 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 6 days after the company's 8-K filed Feb 25, 2025. |
| Feb 3, 2025 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 8,338 sh at $12.70 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 89 days after the company's 8-K filed Nov 6, 2024. | $106K | 178,692 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 89 days after the company's 8-K filed Nov 6, 2024. |
| Nov 30, 2024 | Arcutis Biotherapeutics ARQT | Bought 1,657 sh at $7.11 24 days after the company's 8-K filed Nov 6, 2024. | $12K | 187,030 +1% | 24 days after the company's 8-K filed Nov 6, 2024. |
| Nov 19, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,775 sh at $9.68 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 13 days after the company's 8-K filed Nov 6, 2024. | $17K | 181,373 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 13 days after the company's 8-K filed Nov 6, 2024. |
| Nov 4, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 5,015 sh at $8.68 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 82 days after the company's 10-Q filed Aug 14, 2024. | $44K | 178,273 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 82 days after the company's 10-Q filed Aug 14, 2024. |
| Aug 2, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 5,220 sh at $9.02 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 9 days after the company's 10-Q/A filed Jul 24, 2024. | $47K | 183,288 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 9 days after the company's 10-Q/A filed Jul 24, 2024. |
| May 31, 2024 | Arcutis Biotherapeutics ARQT | Bought 4,000 sh at $1.69 Their first open-market buy here in SEC Tracker's records. 17 days after the company's 8-K filed May 14, 2024. | $7K | 185,373 +2% | Their first open-market buy here in SEC Tracker's records. 17 days after the company's 8-K filed May 14, 2024. |
| May 28, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,775 sh at $9.01 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 14 days after the company's 8-K filed May 14, 2024. | $16K | 188,508 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 14 days after the company's 8-K filed May 14, 2024. |
| May 2, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 5,016 sh at $8.74 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 22 days after the company's 8-K filed Apr 10, 2024. | $44K | 185,408 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 22 days after the company's 8-K filed Apr 10, 2024. |
| Mar 4, 2024 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 3,760 sh at $11.12 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 3 days after the company's 424B5 filed Mar 1, 2024. | $42K | 190,424 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 3 days after the company's 424B5 filed Mar 1, 2024. |
| Nov 21, 2023 | Arcutis Biotherapeutics ARQT | Sold 1,850 sh at $1.98 The filing does not mark this sale as under a Rule 10b5-1 plan. | $4K | 46,634 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| May 31, 2023 | Arcutis Biotherapeutics ARQT | Sold 1,830 sh at $7.80 The filing does not mark this sale as under a Rule 10b5-1 plan. | $14K | 42,146 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Mar 2, 2023 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 1,416 sh at $15.82 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $22K | 18,119 −7% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Mar 2, 2023 | Arcutis Biotherapeutics ARQT | Sold (10b5-1) 18 sh at $16.52 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $297 | 18,101 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Nov 21, 2022 | Arcutis Biotherapeutics ARQT | Sold 1,720 sh at $18.19 The filing does not mark this sale as under a Rule 10b5-1 plan. | $31K | 19,535 −8% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Jun 2, 2022 | Arcutis Biotherapeutics ARQT | Sold 1,795 sh at $19.73 The filing does not mark this sale as under a Rule 10b5-1 plan. | $35K | 16,380 −10% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.